Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | DBH | P09172 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376180 | 0.85 | MAPK14 (0.51) | ALDH1A1L3MBTL1KDM4EMAPK14DBH | |
| SCHEMBL5447810 | 0.79 | ADORA2A (0.52) | ALDH1A1L3MBTL1KDM4EMAPK14DBH | |
| SCHEMBL4480725 | 0.78 | MAPK14 (0.46) | ALDH1A1L3MBTL1KDM4EMAPK14DBH | |
| SCHEMBL13635755 | 0.78 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1KDM4EMAPK14DBH | |
| SCHEMBL3526509 | 0.78 | CDK9 (0.55) | ALDH1A1L3MBTL1KDM4EMAPK14CLPP | |
| SCHEMBL4389631 | 0.77 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1KDM4EMAPK14DBH | |
| SCHEMBL4389676 | 0.76 | MEN1 (0.53) | ALDH1A1L3MBTL1KDM4EMAOB | |
| SCHEMBL11015099 | 0.75 | HPGD (0.63) | ALDH1A1L3MBTL1FFAR1PPARAPOLB | |
| SCHEMBL4377801 | 0.75 | L3MBTL1 (0.49) | ALDH1A1L3MBTL1KDM4EMAPK14DBH | |
| SCHEMBL4378877 | 0.75 | MAPK14 (0.49) | ALDH1A1L3MBTL1KDM4EMAPK14DBH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | claimed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629363-B2 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1490064-B1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | DEVADAS BALEKUDRU | 2007-04-19 | — | — | US | disclosed |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT (US) | 2006-09-21 | — | — | US | disclosed |
| US-7067540-B2 | Substituted pyridinones | PHARMACIA CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | ALDH1A1 787/4885L3MBTL1 3937/4885KDM4E 3869/4885 |
| US-20060211694-A1 | antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease | LTB4R2, LTB4R, MAPK1 | ALDH1A1 1030/4885L3MBTL1 3898/4885KDM4E 4408/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | ALDH1A1 741/4885L3MBTL1 3850/4885KDM4E 3921/4885 |
| US-20070088033-A1 | Diaryl Substituted Pyridinones | MAPK1, MAPK6, MAP3K6 | ALDH1A1 1080/4885L3MBTL1 3437/4885KDM4E 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.